Metaphore & Flagship Pioneering have teamed up with Novo Nordisk to develop 2 next-generation therapies for obesity under which Metaphore will advance foundational & preclinical activities by jointly working with Pioneering Medicines (Flagship’s drug development unit) & Novo Nordisk
The collaboration will use Metaphore’s MIMIC platform to discover & develop therapies targeting GLP-1 receptor & related biology for managing obesity
Moreover, Novo Nordisk will reimburse R&D costs and make a payment of up to $600M as up front, development, & commercial milestones along with annual net-sales-based tiered royalties, shared b/w Metaphore & Pioneering Medicines. It will further participate in upcoming financing rounds for Metaphore
Ref: Metaphore Biotechnologies | Image: Metaphore Biotechnologies
Related News:- Eli Lilly Reports the P-III (SURMOUNT-OSA) Study Data of Tirzepatide in Patients with Obstructive Sleep Apnea (OSA) and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
